Given its pivotal role in cancer cell metabolism, FASN has emerged as a potential therapeutic target. Several FASN inhibitors have been developed and tested in preclinical and clinical studies. Examples include orlistat, C75, and TVB-2640. These inhibitors have shown promise in reducing tumor growth and enhancing the efficacy of conventional therapies. However, the challenge remains to develop FASN inhibitors with high specificity and minimal side effects.
